AmplifiDx Secures Additional $954,213 in Non-Dilutive Funding from NIH’s RADx Tech Program to Advance U.S. COVID-19 Testing Capabilities.
Newark, CA – December 03, 2024 – AmplifiDx (www.amplifidx.com), an “up-and-coming” player in point-of-care (POC) molecular diagnostics, is pleased to announce that it has been awarded an additional $954,213 in non-dilutive funding from the NIH’s Rapid Acceleration of Diagnostics (RADx®) Tech program. This award brings the company’s total NIH funding to $4.51 million through the RADx® Tech program.
“This additional funding will allow us to accelerate the development of our innovative diagnostic system, helping us to bring a rapid, accurate, and affordable testing solution to market that addresses the urgent needs of healthcare providers and patients alike,” said Nancy Schoenbrunner, CEO of AmplifiDx.
The new funding will support the final stages of development of the AmplifiDx DX 100 Platform, which runs the RespiFast™ Test—a next-generation molecular POC diagnostic test designed to detect and differentiate between the most common respiratory pathogens: SARS-CoV-2, Influenza A, Influenza B, and RSV. The test’s quick turnaround and simple handling allow healthcare providers to deliver results during the patient’s visit, enabling immediate treatment and giving patients clarity and peace of mind with timely, informed care.
AmplifiDx is proud to participate in the NIH RADx® Tech program to expand high-performance rapid testing solutions to enhance U.S. pandemic readiness and public health infrastructure. With this next phase of support from the NIH, AmplifiDx will continue to build on its groundbreaking work, advancing innovative diagnostic solutions to improve patient care and public health outcomes.
This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.
For more information about AmplifiDx, the DX 100™ Platform, and the RespiFast™ Test, visit www.amplifidx.com.
